AMIQ EDA Gives AI Agents Access to Essential Design and Verification Data

New DVT MCP Server Product Is Available in Latest Release This release is a major milestone for both our team and our ...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or ...

Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in ...

This viral AI tool is the future. Don’t install it yet

It lives on your devices, works 24/7, makes its own decisions, and has access to your most sensitive files. Think twice before setting OpenClaw loose on your system.